SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society. Urology 2003; 61: 3749
  • 2
    Milsom I, Abrams P, Cardozo L et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 7606
  • 3
    Stewart W, Herzog R, Wein A et al. Prevalence and impact of overactive bladder in the US. Results from the NOBLE program. International Continence Society Meeting, Seoul, Korea 2001 abstract 24
  • 4
    Versi E. Screening initiative confirms widespread prevalence of overactive bladder in American adults. Int Urogynecol J 2001; 12: S13
  • 5
    Jackson S. The patient with an overactive bladder – symptoms and quality of life issues. Urology 1997; 57 (Suppl. 6A): 1822
  • 6
    Abrams P, Coyne K, Schmier J et al. Health-related quality of life in continent overactive bladder subjects: early results from the NOBLE program. International Continence Society Meeting, Tampere, Finland 2000
  • 7
    Wagner TH, Hu T, Bentkover J et al. Health-related consequences of overactive bladder. Am J Manag Care 2002; 8: S598607
  • 8
    Madersbacher H. Denervation techniques. BJU Int 2000; 85 (Suppl. 3): 16
  • 9
    Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000; 55 (Suppl. 5A): 3346
  • 10
    Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment of women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1998; 104: 98893
  • 11
    Yarker YE, Goa KL, Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6: 24362
  • 12
    Hatanaka T, Ukai M, Ohtake A et al. In vitro tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats and monkeys. International Continence Society Meeting, Florence, Italy 2003 abstract 312
  • 13
    Ikeda K, Kobayashi S, Suzuki M et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naun-Schmied Arch Pharmacol 2002; 366: 97103
  • 14
    Ohtake A, Hatanaka T, Ikeda K et al. In vivo bladder selective profile of solifenacin succinate (YM905) over salivary gland in mice and rats. International Continence Society Meeting, Florence, Italy 2003 abstract 297
  • 15
    Smulders RA, Van Alphen WW, Visser JN et al. Multiple dosing with YM905, a novel, bladder-selective antimuscarinic, in healthy men: safety, tolerability, and pharmacokinetics. International Continence Society Meeting, Heidelberg, Germany 2002 abstract 439
  • 16
    Smulders RA, Tan HT, Krauwinkel W et al. A placebo-controlled, dose-rising study in healthy male volunteers to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of YM905. International Continence Society Meeting, Heidelberg, Germany 2002 abstract 438
  • 17
    Kuipers ME, Tran DD, Krauwinkel W et al. Absolute bioavailability of YM905 in healthy male volunteers: a single-dose, randomised, two-period crossover study. International Continence Society Meeting, Heidelberg, Germany 2002 abstract 437
  • 18
    Chapple CR, Arano P, Bosch JLHR et al. YM905 appears effective and well-tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase II, dose-finding study. International Continence Society Meeting, Heidelberg, Germany 2002 abstract 75
  • 19
    Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. Br Med J 2003; 326: 8418
  • 20
    Wein AJ. Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. Exp Opin Invest Drugs 2001; 10: 6583
  • 21
    Cucchi A, Siracusano S, Guarnaschelli C, Rovereto B. Voiding urgency and detrusor contractility in women with overactive bladders. Neurourol Urodyn 2003; 22: 2236
  • 22
    Cardozo L, Kuzmin I, Lisec ML et al. A double-blind, randomised, placebo-controlled trial with YM905 in symptomatic overactive bladder. American Geriatric Society Annual Meeting, Baltimore, Maryland 2003 abstract P74
  • 23
    Gittelman M, Chu F, Klimberg I et al. Two randomized, double-blind, placebo-controlled, fixed-dose, multicenter studies assess the efficacy and safety of daily oral administration of 10 mg YM905 versus placebo in male and female subjects with overactive bladder. American Urological Association Annual Meeting, Chicago, Illinois 2003